Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RGC News 25 September 2025 - 28 December 2025

Regencell Bioscience (RGC) Stock: What to Know After a Sharp Friday Slide, Latest Headlines, and the Setup for Monday

Regencell Bioscience (RGC) Stock: What to Know After a Sharp Friday Slide, Latest Headlines, and the Setup for Monday

NEW YORK, Dec. 27, 2025, 7:48 PM ET — Market closed Regencell Bioscience Holdings Limited (Nasdaq: RGC) is heading into the final trading stretch of 2025 under a brighter spotlight after a volatile week capped by a steep Friday drop—one that stood out even as the broader U.S. market barely moved in a quiet, post-Christmas session. RGC last closed at $21.16 on Friday, Dec. 26, down $3.44 (-13.98%) on the day, according to delayed consolidated market data. FinancialContent+1 That decline followed an active December that has featured wide swings: RGC traded between $20.50 and $24.31 during Friday’s session, while the
28 December 2025
·····
Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

NEW YORK, Dec. 27, 2025, 6:40 a.m. ET — Market closed Regencell Bioscience Holdings Limited (NASDAQ: RGC) stock heads into the weekend after a sharp Friday pullback, closing at $21.16, down 13.98% from the prior close of $24.60, in a move that put the name on multiple “top losers” radars as U.S. markets wrapped up a quiet post-Christmas session. aaii.com+2Investing.com+2 The late-week decline lands amid a broader backdrop that investors have come to associate with RGC in 2025: outsized percentage swings, intermittent liquidity, and a trading narrative that can move faster than traditional biotech fundamentals. In fact, AAII’s market-close recap
27 December 2025
····
Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

New York time check: It is Friday, December 26, 2025, 12:17 p.m. ET in New York. While the broader U.S. market is mostly drifting near record territory in subdued post‑holiday volume, Regencell Bioscience Holdings Limited (Nasdaq: RGC) is doing what it’s become famous for in 2025: moving a lot, on not much liquidity. AP News As of the most recently available intraday quote in late morning trading, RGC was around $21.28, down roughly 13.5% on the day, with a wide intraday range (roughly $20.71–$24.47) and relatively light volume—conditions that can exaggerate price swings in either direction. What’s happening with RGC
26 December 2025
··
Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (Nasdaq: RGC) is once again reminding markets that “biotech stock” plus “low float” can equal “physics optional.” By the close of trading on December 24, RGC finished at $24.60, down 2.57% from the prior close of $25.25, after trading between $24.60 and $26.42 on the day, with roughly 348K shares traded. StockAnalysis+1 That’s the headline tape. The deeper story—what’s making RGC such a recurring character in 2025’s “stock market does weird things” anthology—mixes extreme volatility, concentrated insider ownership, a past 38-for-1 stock split, and a disclosed U.S. Department of Justice (DOJ) inquiry
24 December 2025
·····
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is having one of those “stock market is a strange animal” moments again: the share price is moving sharply on a story dominated less by traditional fundamentals and more by market structure—low float, extreme volatility, and ongoing legal overhang. As of Dec. 24, 2025, RGC was trading around $25.25, up roughly 14% on the day. Below is a complete, publication-ready roundup of what’s new today (12/24/2025), what the most current forecasts/models are implying, and what the latest filings and third‑party analysis say about the risks that keep following this stock
24 December 2025
·····
Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

December 23, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back in the spotlight on Tuesday after another sharp move higher, extending a volatile December run that’s pulled in momentum traders—and raised fresh questions about fundamentals, governance, and legal risk. As of late morning in U.S. trading, RGC was changing hands around the mid‑$23 range after opening higher, with the day’s trading range roughly $22.00–$23.99. StockAnalysis+1 Below is what’s driving the conversation around Regencell stock right now, based on the latest coverage and filings available on December 23, 2025. RGC stock jumps again on Dec. 23 as it trades
23 December 2025
·····
Regencell Bioscience (NASDAQ: RGC) Stock News Today: DOJ Probe, Extreme Volatility, and What Forecasts Say on Dec. 22, 2025

Regencell Bioscience (NASDAQ: RGC) Stock News Today: DOJ Probe, Extreme Volatility, and What Forecasts Say on Dec. 22, 2025

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back in the spotlight on Monday, Dec. 22, 2025, for the same reason it’s been impossible to ignore for most of this year: wild price swings that seem to have a complicated relationship with fundamentals. By late morning in the U.S., RGC was trading around $23 after opening near $19.43, with an intraday range of roughly $19.07 to $24.50—a very large move for a single session, even by small-cap standards. Benzinga Just hours earlier, RGC showed up on a Benzinga “stocks moving premarket” list, down about 3% in pre-market trading after gains in
22 December 2025
··
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Company Profile and Mission Regencell Bioscience is an early-stage biotech company focused on Traditional Chinese Medicine. Headquartered in Causeway Bay, Hong Kong, Regencell researches, develops, and aims to commercialize herbal treatment formulae for neurocognitive disorders – primarily Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) Marketbeat Insidermonkey. The company’s approach is based on the “Sik-Kee Au TCM Brain Theory,” a proprietary herbal methodology developed by the CEO’s father ts2.tech. Founded in 2014 by CEO Yat-Gai Au, Regencell went public on NASDAQ in July 2021 Stockanalysis. The firm positions itself as a socially responsible, mission-driven enterprise: “Our goal is to save and improve the lives of
7 October 2025
·····
Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

RGC’s 2025 Rollercoaster: From Penny Stock to $33B Phenomenon Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock (literally trading under 10 cents) to a meteoric high of $83.60 within months Stockanalysis. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific news or product launch Gurufocus. Instead, a perfect storm of speculative forces sent RGC into the stratosphere. The catalyst was announced in early June: a 38-for-1 stock split. Overnight, Regencell’s share count multiplied and the price per share dropped from
4 October 2025
·····
RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even explored herbal COVID-19 remedies in the past, though these remain experimental Stocktitan. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding (largely from its founder) and IPO proceeds. In the
25 September 2025
·····
1 2

Stock Market Today

Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Go toTop